Posted by Michael Wonder on 26 Jun 2019
Novartis wins Gilenya reprieve as judge blocks generics, for now
25 June 2019 - Novartis has won a U.S. federal court order preventing rival generic makers from selling versions of the Swiss drug maker’s top-selling multiple sclerosis medicine Gilenya in the United States, at least until a patent dispute is resolved.
Novartis had asked for a preliminary injunction to halt generics makers including Dr. Reddy’s Laboratories, Mylan Pharmaceuticals, Torrent Pharma and Aurobindo Pharma, among others, from making or selling a Gilenya copy in the United States until a final decision on a Novartis patent for the medicine.
The judge said letting generics makers sell their versions before the patent dispute was decided would damage the Swiss drugmaker more than those wanting a piece of Gilenya’s market.
